Summary & Overview
HCPCS J3371: Vancomycin HCl Injection, 500 mg
HCPCS Level II code J3371 denotes a 500 mg injection of vancomycin hydrochloride (Mylan) that is specified as not therapeutically equivalent to J3370. As a commonly used parenteral glycopeptide antibiotic, this code identifies administration of vancomycin for serious gram-positive infections where intravenous therapy is indicated. Nationally, billing clarity for antibiotic injections matters for hospital, outpatient infusion centers, and emergency settings due to high frequency of use and cost implications.
Key payers covered in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context for use. The publication discusses benchmarking and reimbursement context, common modifiers encountered in billing lines, and operational considerations for facility and professional billing workflows. Policy and payer coverage nuances that affect claim adjudication and billing practice are summarized so readers can understand how this HCPCS Level II code is applied across care settings. Data not available in the input is noted where relevant.
Billing Code Overview
HCPCS Level II code J3371 represents an injection of vancomycin hydrochloride (Mylan), 500 mg, specified as not therapeutically equivalent to J3370. This code describes a parenteral antimicrobial medication intended for intravenous administration for treatment of serious gram-positive infections.
Service type: Injectable antimicrobial therapy (intravenous)
Typical site of service: Hospital inpatient, hospital outpatient, emergency department, and other facility-based infusion settings where parenteral antibiotics are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J3371 is an adult or pediatric patient with a serious gram-positive infection requiring intravenous vancomycin where the branded or manufacturer-specific product described by J3371 (vancomycin HCl, Mylan, 500 mg) is used and is documented as not therapeutically equivalent to J3370. A common scenario is a hospitalized patient with suspected or confirmed methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, complicated skin and soft tissue infection, or post-operative surgical site infection who requires IV vancomycin dosing and therapeutic drug monitoring.
The clinical workflow: the admitting team documents the indication and orders IV vancomycin. Pharmacy verifies the exact product and supplies the J3371 vial(s). Nursing prepares and administers the IV infusion per facility protocol, documents lot number and dose, and monitors for infusion-related reactions (including Red Man Syndrome). Pharmacy and laboratory coordinate serum trough or area-under-curve monitoring and adjust dosing. Billing applies J3371 per 500 mg unit supplied, with applicable modifiers for circumstances such as increased procedural services, discontinued services, or supervision status.
Coding Specifications
| Modifier | Description | When to Use |
|---|